Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

April 8, 2008

McKesson Gets Out of Pharmacy Outsourcing

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Adam Fein, PhD, Founder & PresidentAdam Fein, PhD
Founder & President, Pembroke Consulting Inc
Implications: McKesson (MCK) is selling its pharmacy outsourcing business to Comprehensive Pharmacy Services (CPS). McKesson has been the most active out of the big 3 in adjusting its health care business portfolio. For example, the company sold its acute care supply business to Owens & Minor last year. Last week, McKesson acquired Rosebud Solutions, a provider of software solutions to track and manage instruments, endoscopes and tissue implants for surgical services. I expect McKesson to continue tweaking its business mix over the coming year.

Analysis:

Each of the big 3 wholesalers, which also includes AmerisourceBergen (ABC) and Cardinal Health (CAH), have businesses that operate institutional pharmacies on an outsourced basis. I discuss the controversy around the outsourcing business last month in The Dark Side of Pharmacy Outsourcing (Council Site). As you may recall from that post, I'm skeptical of the claim that problems at a single hospital indicated systemic flaws in the pharmacy outsourcing business.

You can read more about McKesson’s business at the McKesson Medication Management page. As a guess, Medication Management probably represents less than $1 billion in revenue but has better 2 to 3 times better profitability than the core drug distribution business. In the absence of any formal statement from the company, I presume that the risks and controversy did not outweigh these incremental profits.



Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-07T13:45:18.680